{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094391","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2026-08-12T10:30:30+00:00","discovered_at":"2026-08-12T10:35:00.747403+00:00","generated_at":"2026-08-12T10:35:10.188782+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track","bullets":["Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B","Q4 GAAP EPS $0.35 vs $(0.11) prior year; adjusted EPS $0.52 vs $0.53","FY26 GAAP EPS $1.16 vs $0.46; adjusted EPS $1.93 vs $1.92","Quarterly dividend $0.08/share, payable Sept 4, 2026, record Aug 24","Merck KGaA acquisition at $73/share cash, ~$11.3B EV, on track"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094391","json":"https://secwatch.observer/filing/0001104659-26-094391.json","markdown":"https://secwatch.observer/filing/0001104659-26-094391.md","text":"https://secwatch.observer/filing/0001104659-26-094391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/0001104659-26-094391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T10:35:10.188782+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}